IP Library Granted Patent US 10,542,909
Granted Patent B2
US 10,542,909 · App. 15/474,811 · Granted Jan 28, 2020

Communication system with partial power source

Inventors: Mark Zdeblick (Portola Valley, CA); Timothy Robertson (Belmont, CA); Aleksandr Pikelny (Los Angeles, CA); Hooman Hafezi (Redwood City, CA)
Assignee: Proteus Digital Health, Inc.
A61B5/073A61B5/0028A61B5/0031A61B5/07A61B5/076A61B5/1473A61B5/4833A61B5/4839A61B5/681A61B5/6861A61B5/7282A61J3/007G06K7/10168H01Q1/273A61B2560/0214A61B2560/0462A61B2562/08A61B2562/162Y10T29/49117
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,542,909
App. No.
15/474,811
Granted
Jan 28, 2020
Kind
B2
Abstract

The system of the present invention includes a conductive element, an electronic component, and a partial power source in the form of dissimilar materials. Upon contact with a conducting fluid, a voltage potential is created and the power source is completed, which activates the system. The electronic component controls the conductance between the dissimilar materials to produce a unique current signature. The system can be used in a variety of different applications, including as components of ingestible identifiers, such as may be found in ingestible event markers, e.g., pharma-informatics enabled pharmaceutical compositions.

Claims (33)

1. A composition, comprising:

a pharmaceutical product comprising a pharmaceutically acceptable carrier; and

an ingestible event marker coupled to the pharmaceutical product, wherein the ingestible event marker comprises:

a control device; and

a partial power source comprising first and second electrodes formed of dissimilar electrochemical materials configured to contact a conductive fluid and generate a voltage to energize the ingestible event marker;

wherein the control device of the energized ingestible event marker is configured to modulate current flow through the conductive fluid, the modulated current flow defining a unique current signature associated with the ingestible event marker;

wherein the ingestible event marker of the composition is:

coated with an external layer configured to delay activation of the ingestible event marker for a first period of time; and

positioned inside the pharmaceutically acceptable carrier, relative to a perimeter defined by the pharmaceutically acceptable carrier, to delay activation of the ingestible event marker for a second period of time, wherein the ingestible event marker is positioned proximate to the perimeter or proximate to a center of the pharmaceutically acceptable carrier based on an identity of the pharmaceutical product.

2. The composition according to claim 1 , wherein the external layer comprises a homogeneous layer of a single material.

3. The composition according to claim 1 , wherein the external layer comprises two or more distinct materials.

4. The composition according to claim 3 , wherein the two or more distinct materials are present as a multilayer structure.

5. The composition according to claim 1 , wherein the external layer is configured to provide conductive fluid passage through the external layer after contact of the composition with the conductive fluid.

6. The composition according to claim 1 , wherein the external layer is further configured to protect the ingestible event marker in a dicing process.

7. The composition according to claim 1 , wherein the external layer is configured to dissolve in five or more minutes after being in contact with the conducting fluid.

8. The composition according to claim 1 , wherein the external layer is environmentally sensitive.

9. The composition according to claim 8 , wherein the external layer is temperature sensitive.

10. The composition according to claim 8 , wherein the external layer is pH sensitive.

11. The composition according to claim 10 , wherein the external layer is insoluble at a first pH and soluble at a second pH.

12. The composition according to claim 1 , wherein the ingestible event marker is secured inside the pharmaceutically acceptable carrier.

13. The composition according to claim 1 , wherein the first and second electrodes of the ingestible event marker are coated with the external layer.

14. The composition according to claim 1 , wherein the pharmaceutical product further comprises a pharmaceutical material, and wherein the external layer is further configured to prevent the ingestible event marker from being activated by the pharmaceutical material.

15. The composition according to claim 1 , wherein the ingestible event marker is positioned proximate to the perimeter or proximate to the center of the pharmaceutically acceptable carrier further based on a desired activation delay between a time of initial ingestion and activation of the ingestible event marker.

16. A composition, comprising:

a pharmaceutical product comprising a pharmaceutically acceptable carrier; and

an ingestible event marker positioned inside the pharmaceutical product, wherein the ingestible event marker comprises:

a partial power source comprising first and second electrodes formed of dissimilar electrochemical materials, wherein the partial power source is configured to generate a voltage to energize the ingestible event marker upon contact with a conductive fluid; and

a control device configured to modulate current flow through the conductive fluid, wherein the modulated current flow defines a unique current signature;

wherein the ingestible event marker of the composition is:

coated with an external layer configured to at least one of delay activation of the ingestible event marker or protect the ingestible event marker; and

positioned relative to a perimeter defined by the pharmaceutically acceptable carrier to delay activation of the ingestible event marker, wherein the ingestible event marker is positioned proximate to the perimeter or proximate to a center of the pharmaceutically acceptable carrier based on an identity of the pharmaceutical product.

17. The composition according to claim 16 , wherein the first and second electrodes of the ingestible event marker are coated with the external layer.

18. The composition according to claim 16 , wherein the external layer is environmentally sensitive.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: PROTEUS DIGITAL HEALTH INC.,
To: OTSUKA AMERICA PHARMACEUTICAL, INC.
Reel/Frame 068980/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2024
From: OTSUKA AMERICA PHARMACEUTICAL, INC.
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 068980/0277 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: ZDEBLICK, MARK; ROBERTSON, TIMOTHY; PIKELNY, ALEKSANDR; HAFEZI, HOOMAN
To: PROTEUS BIOMEDICAL, INC.
Reel/Frame 044820/0391 →
CHANGE OF NAME Recorded Feb 2, 2018
From: PROTEUS BIOMEDICAL, INC.
To: PROTEUS DIGITAL HEALTH, INC.
Reel/Frame 045252/0127 →
Continuity (10)
Continuation 14865508 · Sep 25, 2015
Continuation 14341639 · Jul 25, 2014
Continuation 13153312 · Jun 3, 2011
Continuation 12564017 · Sep 21, 2009
Continuation 11912475
Provisional Application 60676145 · Apr 28, 2005
Provisional Application 60694078 · Jun 24, 2005
Provisional Application 60713680 · Sep 1, 2005
Provisional Application 60790335 · Apr 7, 2006
Related Publication 20170265813A1 · Sep 21, 2017